pharmaphorum

JULY 19, 2021

A new report published by Medicines Discovery Catapult and CPI details the huge medical and market potential for complex medicines in the UK. Over 50% identified a better understanding of complex medicines by regulators as key to developing this field. The potential for complex medicines is vast.

Life Science 52

Life Science Medicine RNA Vaccination 52

Roots Analysis

OCTOBER 30, 2023

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA 40

RNA Vaccination Vaccine Development 40

pharmaphorum

JULY 21, 2021

Novartis has revealed that the FDA has accepted its resubmission for cholesterol-lowering drug Leqvio – rejected unexpectedly by the US regulator last year – and has set a new action date of 1 January 2022.

Sales 52

Sales Gene Therapy RNA Production 52

pharmaphorum

OCTOBER 22, 2020

Roche may not be the first company that comes to mind for a COVID-19 treatment, but the Swiss firm is taking a big swing at the market to rival Gilead’s remdesivir. . AT-527 works by blocking the viral RNA polymerase enzyme needed for viral replication.

Development 66

Development Branding Manufacturing RNA 66

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. Non-coding RNAs include antisense oligonucleotides (ASOs) and RNA aptamers.

RNA 40

RNA Protein Genetics Gene Expression 40

pharmaphorum

JANUARY 5, 2022

New oral therapies join the existing monoclonal antibody cocktails and include molnupiravir (Lagevrio, Merck) and a combination of the new antiviral nirmatrelvir with the HIV antiviral ritonavir (Paxlovid, Pfizer). New COVID-19 treatments will also be available in 2022, but they are not a panacea.

Vaccination 98

Vaccination Vaccine Antibody FDA Approval 98

pharmaphorum

DECEMBER 21, 2020

But the tragic events of 2020 have meant these companies have become household names as their trailblazing mRNA vaccines became the first to be approved by regulators against the COVID-19 scourge. Their technology is based on synthetic messenger RNA – short for ribose nucleic acid – which is a short transcript of a longer DNA code.

Vaccination 111

Vaccination Vaccine Doctors Doctor 111

pharmaphorum

APRIL 28, 2022

Although they have, by definition, small addressable markets, the treatments cost just as many resources to develop as therapies for more common diseases – sometimes more, because of the added difficulty of finding sufficiently large patient populations for trials and finding disease experts to run them.

Pharma Companies 58

Pharma Companies Branding Development Marketing 58

Pharmaceutical Technology

FEBRUARY 1, 2023

AstraZeneca’s Synagis (palivizumab), which was approved in 1998, was the only monoclonal antibody (mAb) available for use to prevent RSV in high-risk infants for the past two decades. As an RNA virus, like SARS-CoV-2, RSV is highly prone to mutations.

Vaccination 162

Vaccination Vaccine Antibody Protein 162

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. million in the second quarter of 2021 for its COVID-19 antibodies. – Revenue from all key products grew in the quarter and 2021 year-to-date. on a non-GAAP basis.

Antibody 52

Antibody Sales Production Development 52

The Pharma Data

JANUARY 6, 2021

.” Based on the collaboration agreement, CureVac will be the Marketing Authorization Holder for the product, while Bayer will support CureVac with country operations within the European Union (EU) and selected additional markets. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros.

Vaccination 52

Vaccination Vaccine Development Marketing 52

XTalks

NOVEMBER 7, 2022

Another method to isolate CTCs is by antibody targeting of white blood cells for removal, followed by collection of untagged CTCs. Also, exosomes are mostly being used for the detection of circulating RNA and microRNA. “An Regulators may ask at some point to provide that documentation, so it’s important to track that across the study.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Drug Discovery World

JULY 11, 2023

Drug discovery and development timelines can span 10-15 years or more from initial discovery to market approval and typically require the analysis of massive amounts of data. In another published report 2 , a biotech company needed to improve its centrifugation step during monoclonal antibody (mAb) harvesting.

Big Data 40

Big Data Development Life Science Drugs 40

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Hiroki Shirai, PhD, Coordinator, RIKEN Center for Computational Science, on: ‘Applying deep learning anomaly detection to antibody structures’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

AUGUST 10, 2022

By Mark White, Associate Director of Biopharma Product Marketing at Bio-Rad and Marwan Alsarraj, Biopharma Segment Manager, Digital Biology Group. Next, the advent of antibody treatments in 1997 created the first targeted cancer therapy 2. Exactly three decades later, the first CAR T cell therapy hit the market.

Manufacturing 98

Manufacturing Gene Genome Genomics 98

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. For more information, visit. www.merck.com. and connect with us on. Every day, Pfizer.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

JANUARY 21, 2021

market specifically target the spike protein to prevent transmission, explained Dr. Kathryn Edwards, scientific director of the Vanderbilt University Vaccine Research Program in Nashville. “The height of the antibody response may be somewhat proportional to how sick you are in the beginning. “The spike is really critical.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. 2022 Revenue: Pfizer reported an annual revenue of $100.33 Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Drug Discovery World

APRIL 12, 2023

According to a McKinsey & Company article 2 , new drug modalities (such as RNA therapeutics, protein degraders, cyclopeptides, ADCs, cell and gene therapies) have almost doubled from 11% to 21% of the drug pipeline. For some pharmaceutical companies, like AstraZeneca 3 , 30% of their early pipeline consists of new drug modalities.

Development 52

Development In-Vivo Drugs In-Vitro 52

Drug Discovery World

JANUARY 20, 2023

According to a McKinsey & Company article 2 , new drug modalities (such as RNA therapeutics, protein degraders, cyclopeptides, ADCs, cell and gene therapies) have almost doubled from 11% to 21% of the drug pipeline. For some pharmaceutical companies, like AstraZeneca 3 , 30% of their early pipeline consists of new drug modalities.

Development 52

Development In-Vivo Drugs In-Vitro 52

XTalks

AUGUST 30, 2022

CNS drugs take more than a year longer to develop and are less than half as likely to receive marketing approval compared to other drugs, according to a 2014 study by the Tufts Center for the Study of Drug Development. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets?

Trials 83

Trials Drug Delivery Drugs Gene 83

The Pharma Data

JANUARY 4, 2021

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Israel’s Ministry of Health (MOH) has given authorization to import the COVID-19 Vaccine Moderna in Israel. We hope to continue to see authorizations in additional markets in the coming days, weeks and months.”.

Vaccination 52

Vaccination Vaccine Medicine Containment 52

XTalks

DECEMBER 24, 2020

Most antibody drugs and vaccines have been developed to target parts of the spike protein. These include remdesivir, baricitinib, dexamethasone and three antibody drugs. Antibody drugs were also developed as targeted COVID-19 treatments. Drug Approvals.

Life Science 111

Life Science Vaccination Vaccine Gene 111

Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. This design protects antibodies from the innate immune system. And the issue is that antibodies are too big to go directly inside the cell,” he says.

Drug Delivery 147

Drug Delivery Vaccination Vaccine Research 147

XTalks

SEPTEMBER 14, 2020

Moderna, for one, recently reported positive results in older adults between 56 and 71, as well as those 71 years of age and older, who reportedly mounted levels of neutralizing antibodies against the SARS-CoV-2 virus after two doses of its vaccine that were comparable to those seen in younger adults. Johnson & Johnson’s COVID-19 Vaccine.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92